This was an Australasian Bone Marrow Transplant Recipient Registry (ABMTRR)-based retrospective study assessing the outcome of Fludarabine Melphalan (FluMel) reduced-intensity conditioning between 1998 and 2008. Median follow-up was 3.4 years. There were 344 patients with a median age of 54 years . In all, 234 patients had myeloid malignancies, with AML (n ¼ 166) being the commonest indication. There were 110 lymphoid patients with non-hodgkins lymphoma (NHL) (n ¼ 64) the main indication. TRM at day 100 was 14% with no significant difference between the groups. OS and disease-free survival (DFS) were similar between myeloid and lymphoid patients (57 and 50% at 3 years, respectively). There was no difference in cumulative incidence of relapse or GVHD between groups. Multivariate analysis revealed four significant adverse risk factors for DFS: donor other than HLAidentical sibling donor, not in remission at transplant, previous autologous transplant and recipient CMV positive. Chronic GVHD was associated with improved DFS in multivariate analysis predominantly due to a marked reduction in relapse (HR:0.44, P ¼ 0.003). This study confirms that FluMel provides durable and equivalent remissions in both myeloid and lymphoid malignancies. Disease stage and chronic GVHD remain important determinants of outcome for FluMel allografting.
INTRODUCTION
Allogeneic haemopoietic SCT (HSCT) is a potentially curative procedure for a wide range of haematological malignancies, but the benefit of the graft versus malignancy (GVM) effect is often offset by increased toxicity of GVHD and infection. 1 Reduced-intensity conditioning (RIC) regimens have become more commonly used over the last 10 years in HSCT in an attempt to provide the potential curative benefit of allografting to a wider patient population. 2 In general, RIC benefits patients who are older with more co-morbidities, and thus cannot tolerate the more conventional myeloablative conditioning. Several studies have demonstrated that the choice of RIC in these patients appears to result in less TRM while maintaining some GVM effect. 3, 4 As a consequence, RIC regimens now account for up to 40% of all unrelated allografts in Australia, 5 and yet there have been limited major studies on this form of transplantation.
RIC regimens began to be used commonly in Australia and New Zealand from 1998, as has previously been reported by the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR). 6 Similarly the European BMT Registry (EBMT) has demonstrated a rapid uptake of RIC HSCT from 1998. 7 In Australia and New Zealand, the most commonly used RIC regimen is Fludarabine Melphalan (FluMel) with or without in vivo T-cell depletion, 5 as initially described by Giralt et al. 8 At the recent Centre for International Bone Marrow Transplant Registry (CIBMTR) consensus meeting, FluMel p140 mg/m 2 was voted as one of the more common regimens used for RIC and considered to be a RIC regimen by 75% of attendees. 9 This recommendation from the panel of experts at the CIBMTR conference suggests a high utilisation of FluMel throughout the HSCT community; however, there are few large studies with more than 200 patients.
Most published literature on RIC transplantation has concentrated on single diseases and the relative benefit of a particular form of RIC in that disease setting. There have been few studies analysing a commonly used regimen and assessing its benefit across several disease groups. Given that patients with lymphoid malignancies are often more heavily treated than myeloid patients before allograft, we hypothezised that lymphoid patients would have an inferior outcome from FluMel conditioning due to increased toxicity and resistant disease. In this study, we retrospectively assess the relative benefits of FluMel RIC HSCT from 1998 to 2008, in a large cohort of patients with either lymphoid or myeloid malignancies.
MATERIALS AND METHODS

Study design
recipients were selected from the ABMTRR, which has recorded more than 95% of all HSCT activity in Australia since 1992 and in New Zealand since 1998. 6 Patients were eligible for the study if they were older than 18 years of age and received a first allogeneic peripheral blood or BM HSCT using FluMel conditioning for lymphoid and myeloid malignancies (excluding multiple myeloma and AML) between January 1998 and December 2008 at one of seven Australian and two New Zealand adult transplant centres. Patients receiving allogeneic HSCT following single or tandem autologous HSCT were included, but second or third allogeneic HSCT were excluded. Patient consent for data to be recorded on the ABMTRR database is obtained by individual participating institutions. This study was approved by the ABMTRR Steering Committee. Identification of eligible patients and the veracity of the submitted data were the responsibility of the contributing centre, although key information was cross referenced by the principal investigators with the ABMTRR).
Conditioning regimen and definitions
The conditioning regimen consisted of fludarabine 25-30 mg/m 2 intravenously for 5 days (day À 6 to day À 2) and melphalan 120-160 mg/m 2 on day À 1. The choice of dose within these ranges for fludarabine and melphalan reflected the practice of the individual centre. Patients received GVHD and antimicrobial prophylaxis according to the practice of the individual centre. Patients and donors were considered HLA-identical if they were matched at 6 of 6A-, B-and DR-loci at high resolution if available, otherwise serological level. HLA-typing data and information with respect to HLA matching was as reported by each individual centre, however the registry only obtained information at the serological level. Data with respect to high resolution matching were not routinely available for analysis, and therefore could not be included in this study.
Day of neutrophil engraftment was defined as the first of three consecutive days of a blood neutrophil count of 0.5 Â 10 9 /L or above. Day of platelet engraftment was defined as the first day when the blood platelet count was 20 Â 10 9 /L or above, and there had been no platelet transfusions in the previous 7 days. International Bone Marrow Transplant Registry (IBMTR) criteria were used to grade acute GVHD, 10 whereas chronic GVHD was defined as limited or extensive.
11 TRM was defined as death post transplant from all causes other than relapse or persistent disease. Cytogenetic risk in AML was assigned hierarchically according to Grimwade et al. 12 Statistical analysis Primary end points were OS and disease-free survival (DFS). Secondary end points were engraftment, TRM, acute and chronic GVHD and relapse post transplant. Post transplant OS and PFS probabilities were evaluated using Kaplan-Meier (KM) curves that were compared using log-rank tests. Cumulative incidence curves for engraftment, TRM, GVHD and relapse were constructed treating death from relapse of the underlying disease and death from non-relapse causes as competing risks. 13 The following variables were tested for association with acute GVHD, TRM, relapse, OS and DFS: transplant year (before 2006), cytogenetics at diagnosis (myeloid malignancies only), number of previous chemotherapy regimens, previous autologous HCT, co-morbid conditions, donor and recipient CMV status, T-cell depletion using antithymocyte globulin (ATG)/ Campath, cyclosporin/MTX GVHD prophylaxis, melphalan dose, number of CD34 þ cells infused (dichotomous variable pivoting at 5 Â 10 6 CD34 þ cells per kg), lymphoid/myeloid malignancy, sex, age, cell source, donor relation and HLA compatibility, remission status at transplant, and presence of acute and chronic GVHD (note that acute and chronic GVHD were only included in the multivariate analysis for TRM, relapse, OS and DFS). P o0.05 was considered significant.
Values that had a significant effect on univariate analysis for each of the tested outcomes were subjected to multivariate analysis, which was carried out using Cox regression. The least significant variables were progressively removed from the model until only those with P o0.05 remained. All statistical analyses were carried out using Stata statistical software Release 10 (Statacorp LP, College Station, TX, USA). The close-out date for this study was 31 December 2010.
RESULTS
Patient demographics and indications for transplantation
The number of first allografts performed at the nine participating centres over the period 1998-2008 for myeloid and lymphoid malignancies was n ¼ 1907 (all were aged 15 þ ). Of these, n ¼ 344 or 18% were performed with Flu/Mel conditioning and had available data for inclusion in this study. This group included 110 transplanted for lymphoid disease and 234 for myeloid disease ( Table 1 ). The median follow-up time was 3.4 years (range: 0.06-9.9). The age distribution differed significantly between the myeloid and lymphoid groups. RIC allografts for myeloid patients were more commonly employed in recipients aged 450 years (85% myeloid versus 47% lymphoid), and the median age was significantly older (56 versus 49 years, Po0.001).
Lymphoid patients were more likely to have undergone a previous autologous HSCT (40% versus 15%, Po0.001). Similarly, lymphoid patients were significantly more likely to have had more chemotherapeutic regimens before HSCT (41% of lymphoid patients had received three or more regimens versus 10% myeloid, Po0.001). Among the lymphoid indications, the malignancies most frequently subject to RIC transplantation were CLL (CLL-28%), follicular lymphoma (FL-28%), Hodgkin lymphoma (HL-11%) and diffuse large B-cell lymphoma (DLBCL-11%).
AML accounted for a vast majority of the myeloid indications (71%), with myelodysplastic syndrome (MDS) the next most frequent (17%). Myeloid patients were significantly more likely to be in remission at the time of allografting (CR1/2: 52% versus 33%, Po0.001). Among patients with AML, 1.5% had favourable risk, 54.8% had standard risk and 22.3% had poor risk cytogenetics (21.7% unknown). Table 2 , the melphalan component of most patients' conditioning was dosed at either 140 mg/m 2 (65%) or 120 mg/m 2 (32%), according to the individual centre's preferences. Pharmacological in vivo T-cell depletion was deployed before stem cell reinfusion in a minority of recipients (22%) using either antithymocyte globulin (ATG) or alemtuzumab, according to the individual centre's preferences. Among the 134 unrelated donor transplants, 52 (39%) had ATG or Campath, whereas among the 210 sibs/other related, 22 (10%) had these compounds. Stem cells from related donors were used in 210 patients (61%), whereas 121 (39%) were from unrelated donors (11% of whom were mismatched at 1/6 Ags). PBSC were the stem cell source in 94% of patients with no difference in source between lymphoid and myeloid groups. The median CD34 þ cell dose infused was 5.0 Â 10 6 /kg (range: 1.2-92.2) with no difference between the groups. The majority of patients (67%) in both groups had cyclosporin and MTX as GVHD prophylaxis.
Transplant characteristics As outlined in
Transplant outcome and GVHD Outcomes of the HSCT are outlined in Table 3 . The median times to neutrophil and platelet engraftment were 16 and 18 days, respectively, and did not differ significantly between the lymphoid and myeloid groups. Severe acute GVHD (grades II-IV) was seen in 47% of lymphoid patients, compared with 39% of myeloid patients. CMV reactivation was significantly more frequent in lymphoid rather than myeloid patients (38% versus 16%; Po0.001). In contrast, myeloid patients appeared more prone to the development of microangipathic haemolytic anaemia (MAHA) (3% versus 18%; Po0.001) than lymphoid patients, which was seen in 13% of evaluable patients overall.
Among the 134 unrelated donor transplants, 52 (39%) had ATG or Campath, whereas among the 210 sibs/other related, 22 (10%) had these compounds. Overall, 70% of 256 evaluable patients (that is, alive at 100 days) developed cGVHD. Of the 56 patients who had ATG or Campath, 29 or 52% developed cGVHD, whereas of the 200 who did not have ATG or Campath, 149 or 75% developed cGVHD (P ¼ 0.002).
Of the lymphoid patients who were not in remission at transplant (n ¼ 70), 51 (73%) subsequently attained remission post transplant, whereas of the n ¼ 104 myeloid patients who were not in remission at transplant, 85 (82%) attained remission post transplant (P ¼ 0.2).
There were no significant differences between lymphoid and myeloid groups in TRM, risk of relapse or DFS and OS. Overall TRM was 14% at 100 days and 22% at 1 year. The overall cumulative incidence of relapse at 1, 2 and 3 years post transplantation was 13%, 18% and 20%, respectively. The similarity in outcome between the groups was also seen in the survival analysis. FluMel RIC transplants in Australasia afforded lymphoid and myeloid patients an OS of 59% versus 57% at 3 years (P ¼ 0.5, Figure 1a ), whereas the DFS was 48% versus 51% (P ¼ 0.8, Figure 1b) .
Within the lymphoid disease category, patients with CLL or follicular lymphoma had an OS of 64% at 3 years, whereas patients with diffuse large cell B-cell lymphoma only had an OS of 33% at 3 years (P ¼ 0.06, Figure 2b) .
Death was was due to relapse and progressive disease in 27% and 5% of patients (who died), respectively, and because of infection, GVHD and organ toxicity in 25%, 17% and 13% of patients, respectively.
Multivariate analysis
Results of a multivariate analysis are outlined in Table 4 . Cox multivariate regressions were carried out on incidence of acute GVHD, TRM, OS, DFS and 'incidence of relapse', testing the effects of the independent variables listed above. Non-remission at transplant (P ¼ 0.01), donor other than HLA-identical sibling donor (P ¼ 0.01) and prior autologous transplantation (P ¼ 0.002) were adversely associated with OS. These three poor prognostic factors were also associated with inferior TRM and DFS. CMV recipient positivity was adversely associated with DFS (P ¼ 0.01). Chronic GVHD (P ¼ 0.03) was associated with a greater OS and a lower rate of relapse. The survival advantage imparted by chronic GVHD was independently significant of whether or not patients had received CAMPATH/ATG.
AML subanalysis and multivariate analysis. AML was the major indication for FluMel allografting in this series. OS at 3 years for AML was strongly associated with remission status (CR1 60%, CR2 64% and not in remission 37%) at 3 years post transplant (P ¼ 0.004, Figure 2a) . On a separate multivariate analysis of AML patients (Table 5) , factors adversely affecting OS FluMel conditioning in myeloid and lymphoid malignancies A Bryant et al were remission status (Po0.001) and use of a CMV-positive recipient (P ¼ 0.01). Chronic GVHD (P ¼ 0.01), cyclosporin/MTX GVHD prophylaxis (P ¼ 0.009) and a CMV-positive donor (Po0.001) were positively associated with OS.
DISCUSSION
Despite the relative curative potential of allogeneic haematopoietic SCT, its application has, until the last 10 years, been restricted to patients who could tolerate a myeloablative procedure. The advent of RIC HSCT provided many more patients the option of cure of their haematological malignancies via the putative 'graft versus malignancy' effect. However, the choice of conditioning regimens has largely been at the discretion of individual centres, without a thorough understanding of their relative benefits in certain diseases. This analysis provides insight into the RIC regimen of FluMel by demonstrating that it has significant activity in both myeloid and lymphoid malignancies.
Despite the poor-risk patient population in this study (median age 54 with 73% older than 50 and only 49% in remission at HSCT), 85% of patients achieved CR post HSCT with a 57% OS at 3 years, suggesting that there is a strong GVM effect. A cumulative incidence of relapse of only 20% with no difference between myeloid and lymphoid diseases provides evidence for the FluMel conditioning in myeloid and lymphoid malignancies A Bryant et al magnitude of this GVM effect. This relatively low relapse rate suggests that FluMel conditioning provides a microenvironment conducive for the antitumour effect of donor T cells. The strong association of chronic GVHD with reduced relapse in multivariate analysis further confirms the GVM effect in this study. Melphalan is an attractive option for RIC HSCT as it provides broad antitumour activity to a wide range of haematological malignancies.
14 In addition, when combined with fludarabine, the combination is highly immunosuppressive, thus providing an excellent platform for rapid engraftment and the GVM effect. Surprisingly, despite its widespread use in both lymphoid 15 and myeloid malignancies, 16 there have been few large studies comparing this commonly used regimen in multiple malignancies.
This study confirms that FluMel conditioning can be performed safely in patients with both lymphoid and myeloid malignancies. Outcomes are similar using this regimen in both tumour groups, suggesting that FluMel has wide applicability in haematological malignancies. To our knowledge this is one of the largest published analyses of FluMel RIC conditioning, providing important data to guide therapeutic decision making in the future.
The predominant malignancies treated in the myeloid group were AML and MDS (comprising 88% of all patients). Although there have been numerous other studies assessing the role of FluMel in these conditions, 17, 18 each was reported with a shorter follow-up. The current study has confirmed, with extended followup, that disease stage is the single most important prognostic factor for outcome. In addition, this and other studies have confirmed the equivalent DFS/OS of unrelated and sibling donors in AML. This is in contrast to other malignancies in this analysis where the use of an unrelated donor resulted in inferior outcome. In this study, CMV recipient positivity was demonstrated to be an adverse factor for outcome in AML, a finding that has previously been demonstrated in the myeloablative setting in an ABMTRR study. 19 These data confirm the excellent outcome of CMV seronegative recipients in remission at transplant whether in the RIC or myeloablative setting. Interestingly, the presence of chronic GVHD was protective against relapse in this study. In contrast, studies using T-cell depleted grafts in AML have not shown a beneficial effect of chronic GVHD, suggesting that agents, such as Campath, may abrogate chronic GVHD and possibly the putative graft versus leukaemia effect. 17 Luger et al. 20 have recently published an analysis of RIC for AML/MDS compared with non-myeloablative conditioning (Flu/TBI 200, Flu Cy) and myeloablative conditioning. This CIBMTR analysis demonstrated that RIC regimens (including FluMel) provide similar outcomes to myeloablative conditioning, suggesting that FluMel remains a valid conditioning choice in AML/MDS. Nevertheless, randomised trials are warranted to adequately assess the role of RIC versus myeloablative conditioning in AML/MDS.
For lymphoid malignancies, this study confirms findings of other studies that remission status at transplant is vitally important for long-term disease control. 21, 22 The UK group has demonstrated that Follicular NHL appears to be particularly responsive to FluMel Campath conditioning 23 compared with more aggressive forms of NHL such as DLBCL. 22 In this current study, there was no significant difference in DFS and OS between these two forms of NHL; however, this may be due to smaller numbers of those malignancies than in the UK studies. This analysis did, however, confirm the UK group's conclusion that autograft before the RIC allograft in NHL resulted in inferior outcomes in lymphoid malignancies. 23 This finding suggests that the decision to perform autografts in NHL (particularly in Follicular NHL) may need to be reconsidered if an allograft can be envisaged in future management. Given that prior autografting remained a significant factor for TRM in the multivariate analysis, it is likely that an autograft is indicative of more heavily pre-treated patients leading to increased toxicity.
The major limitation of this study is its retrospective design. The patient groups were very heterogenous, and the reasons for the choice of FluMel conditioning (both with respect to the overall decision to proceed to RIC transplantation over myeloablative conditioning, as well as choice of specific fludarabine and melphalan dosing in the RIC regimen) are not known. Although a comparison was made between lymphoid and myeloid diseases, there were significant differences between the two cohorts in remission status making conclusions about disease control in remission difficult to interpret. Nevertheless it is clear that this study has confirmed that FluMel is an important RIC regimen to be considered for poor risk patients. Future research is warranted to compare different RIC regimens in specific diseases preferably in prospective randomised designs. The relative benefit of myeloablative conditioning compared with FluMel or other RIC regimens is an important question in AML, as is the use of FluMel compared with non-myeloablative regimens in lymphoid malignancies.
It was our overall hypothesis that outcomes may be poorer in lymphoid compared with myeloid patients receiving FluMel. However, OS and DFS were not significantly different between these groups, although it is recognised that it is difficult to directly compare the risk status of patients in each group. This analysis confirms that FluMel conditioning can be used in a wide range of haematological malignancies with excellent tumour control. FluMel continues to be a popular choice for RIC transplants worldwide, and further studies to assess its place in management of individual diseases are warranted. FluMel conditioning in myeloid and lymphoid malignancies A Bryant et al
